Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?

Abstract EN

Background and Objectives.

Triple negative breast cancer (TNBC) has been shown to be generally chemosensitive.

We sought to investigate the utility of mammography (MMG), ultrasonography (US), and breast magnetic resonance imaging (MRI) in predicting residual disease following neoadjuvant chemotherapy for TNBC.

Methods.

We identified 148 patients with 151 Stage I–III TNBC treated with neoadjuvant chemotherapy.

Residual tumor size was estimated by MMG, US, and/or MRI prior to surgical intervention and compared to the subsequent pathologic residual tumor size.

Data were compared using chi-squared test.

Results.

Of 151 tumors, 44 (29%) did not have imaging performed prior to surgical treatment.

Thirty-eight (25%) tumors underwent a pathologic complete response (pCR), while 113 (75%) had residual invasive disease.

The imaging modality was accurate to within 1 cm of the final pathologic residual disease in 74 (69%) cases and within 2 cm in 94 (88%) cases.

Groups were similar with regards to patient age, race, tumor size and grade, and clinical stage (P>0.05).

Accuracy to within 1 cm was the highest for US (83%) and the lowest for MMG (56%) (P<0.05).

Conclusions.

Breast US and MRI were more accurate than MMG in predicting residual tumor size following neoadjuvant chemotherapy in patients with TNBC.

None of the imaging modalities were predictive of a pCR.